A Better Way Forward in Opioid Withdrawal Management
Wearable Neurostimulation for Opioid Withdrawal
Effective Opioid Withdrawal Management for Better Patient Outcomes
Whether transitioning patients to MAT/MOUD or helping them eliminate opioids from daily life, rapidly managing opioid withdrawal is a pivotal first step for patients with Opioid Use Disorder (OUD).
For providers, it’s a critical moment in which to stabilize patients or quickly lose them to discharge against medical advice (AMA). In fact, studies show that approximately 10% of patients leave AMA in the first three days of treatment – many of which due to unmanaged withdrawal.¹
Introducing Sparrow Ascent, the better way forward for withdrawal management.
Sparrow Ascent changes the way opioid withdrawal is managed, offering a non-invasive, FDA-cleared solution that directly targets all withdrawal symptoms without introducing drug interactions or systemic side effects.
What Makes Sparrow Ascent Different?
As the first FDA-cleared, non-invasive, wearable neurostimulation device for opioid withdrawal relief, Sparrow Ascent offers:
A Drug-Free/Non-Invasive Option –no systemic side effects, no drug interactions, no needles.
Begins working in as little as 30 minutes; 84% of patients report mild to no symptoms within an hour.
Proven Efficacy – 100% of participants in clinical trials sustained meaningful relief at day 3 and beyond.
Clinical Advantages to Incorporating Sparrow Ascent
High withdrawal-related AMA rates can disrupt treatment goals and drain resources. Sparrow Ascent empowers centers with:
A Resource to Reduce Early Discharges – Put a tool in your toolkit to lower the withdrawal-related AMA rate in the first three days of care.
Optimize Resource Management – Reduce high acuity patient burden on staff with a safe, fast-acting, flexible approach to withdrawal management.
Enhance Patient Engagement – 90% of patients completing detox with Sparrow Ascent continued to the next treatment step.
Maximize Patient Access – Sparrow Ascent can be used across IP, OP and In-home care settings allowing unique treatment options not yet offered by other centers.
Clinical Results at a Glance
of participants experienced mild or no withdrawal symptoms after 60 minutes of therapy.
of participants sustained a clinically meaningful reduction in withdrawal symptoms by day 3.
participants who completed detox accepted a referral to continue opioid use disorder treatment.
PHQ-9 and BCL-5 Results
Clinical trial participants also experienced reduction in Depression and PTSD – helping support the recovery journey.
of participants had clinically meaningful reduction in PHQ-9 scores at day 5
of participants sustained a clinically meaningful reduction in withdrawal symptoms by day 3.
Publications & Clinical Trials
At Spark Biomedical, we drive scientific progress through pioneering research, clinical trials, and bringing innovative solutions to market. Below are our efforts supporting solutions in opioid use disorder. See all of our scientific progress on The Neuroscience page.
Publications
Frontiers
Transcutaneous Auricular Neurostimulation (tAN): A Novel Adjuvant Treatment in Neonatal Opioid Withdrawal Syndrome
Bioelectronic Medicine
Delivering transcutaneous auricular neurostimulation (tAN®) to improve symptoms associated with opioid withdrawal: results from a prospective clinical trial
Sparrow Ascent Providers
Success Stories
Looking for More Information?
Not ready to purchase?
Complete this form to download the Clinical Trial Whitepaper.
